GINMU >

Browsing by Author Tsuji, Yuki

Issue Date	Title	Author(s)
19-Jun-2020	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis.	Tsuji, Yuki; Kaji, Kosuke; Kitade, Mitsuteru; Kaya, Daisuke; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Moriya, Kei; Akahane, Takemi; Yoshiji, Hitoshi
Dec-2019	Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model.	Kubo, Takuya; Kawaratani, Hideto; Sawada, Yasuhiko; Fujinaga, Yukihisa; Ozutsumi, Takahiro; Kaya, Daisuke; Tsuji, Yuki; Nakanishi, Keisuke; Furukawa, Masanori; Kitagawa, Kou; Saikawa, Soichiro; Sato, Shinya; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
Oct-2019	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.	Shimozato, Naotaka; Namisaki, Tadashi; Kaji, Kosuke; Kitade, Mitsuteru; Okura, Yasushi; Sato, Shinya; Moriya, Kei; Seki, Kenichiro; Kawaratani, Hideto; Takaya, Hiroaki; Sawada, Yasuhiko; Saikawa, Soichiro; Nakanishi, Keisuke; Furukawa, Masanori; Fujinaga, Yukihisa; Kubo, Takuya; Asada, Kiyoshi; Kitagawa, Koh; Tsuji, Yuki; Kaya, Daisuke; Ozutsumi, Takahiro; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
21-Mar-2020	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.	Ozutsumi, Takahiro; Namisaki, Tadashi; Shimozato, Naotaka; Kaji, Kosuke; Tsuji, Yuki; Kaya, Daisuke; Fujinaga, Yukihisa; Furukawa, Masanori; Nakanishi, Keisuke; Sato, Shinya; Sawada, Yasuhiko; Saikawa, Soichiro; Kitagawa, Koh; Takaya, Hiroaki; Kawaratani, Hideto; Kitade, Mitsuteru; Moriya, Kei; Noguchi, Ryuichi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
4-Aug-2020	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.	Fujinaga, Yukihisa; Kawaratani, Hideto; Kaya, Daisuke; Tsuji, Yuki; Ozutsumi, Takahiro; Furukawa, Masanori; Kitagawa, Koh; Sato, Shinya; Nishimura, Norihisa; Sawada, Yasuhiko; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
Oct-2022	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis	Enomoto, Masahide; Kaji, Kosuke; Nishimura, Norihisa; Fujimoto, Yuki; Murata, Koji; Takeda, Soichi; Tsuji, Yuki; Fujinaga, Yukihisa; Tanaka, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Aug-2022	Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis	Murata, Koji; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Fujimoto, Yuki; Takeda, Soichi; Tsuji, Yuki; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
26-Sep-2019	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.	Kaya, Daisuke; Kaji, Kosuke; Tsuji, Yuki; Yamashita, Satoko; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi